Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 377 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RBV Clear all
Completed Phase 3 Interventional Results available

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

NCT01448044
View directory record Official record
Conditions
Hepatitis C
Interventions
BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Results available

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

NCT00107653
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, Peginterferon alfa-2a
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
58
States / cities
Scottsdale, Arizona • Tucson, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 2 Interventional

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

NCT01057667
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
RO5024048, Ribavirin [Copegus], peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
La Jolla, California • Bradenton, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 17, 2026, 4:39 AM EDT
Not listed Phase 4 Interventional

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

NCT01731301
View directory record Official record
Conditions
Chronic Hepatitis C, End Stage Renal Disease
Interventions
Ribavirin, Peginterferon, Boceprevir
Drug
Lead sponsor
Liver Institute of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy

NCT00266318
View directory record Official record
Conditions
Hepatitis C
Interventions
Interferon Alfacon-1 and Ribavirin
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2008 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients

NCT02743897
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Zepatier, Mavyret
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

NCT00593151
View directory record Official record
Conditions
Hepatitis C
Interventions
Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
Other · Biological
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

NCT01445795
View directory record Official record
Conditions
Hepatitis C
Interventions
200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 17, 2026, 4:39 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

NCT01890772
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Peginterferon alfa-2a, Ribavirin, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Timothy Morgan, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
Long Beach, California • Minneapolis, Minnesota • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Respiratory Syncytial Virus - RSV Protocol

NCT01502072
View directory record Official record
Conditions
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia, Cancer, Acute Leukemia
Interventions
Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Results available

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

NCT00793793
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI201335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 17, 2026, 4:39 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

NCT01718158
View directory record Official record
Conditions
Hepatitis C
Interventions
Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin, Daclatasvir, Telaprevir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
Long Beach, California • Marietta, Georgia • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

NCT00336479
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

NCT01290679
View directory record Official record
Conditions
Hepatitis C
Interventions
Placebo, TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Ribavirin (RBV)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 17, 2026, 4:39 AM EDT
Completed No phase listed Observational

Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection

NCT01771653
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Not listed
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 3 Interventional

PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

NCT00215891
View directory record Official record
Conditions
Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections
Interventions
PEG-Interferon a-2b + Ribavirin
Drug
Lead sponsor
Hepatitis Resource Network
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2005 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)

NCT00984620
View directory record Official record
Conditions
Hepatitis C
Interventions
BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
6
States / cities
Tulepo, Mississippi • New York, New York • Germantown, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

NCT01616524
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin, Daclatasvir, Placebo matching Daclatasvir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 4 Interventional

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9

NCT00575224
View directory record Official record
Conditions
Chronic Hepatitis C, Asian Americans, Novel Genotypes, Treatment
Interventions
Pegylated interferon and ribavirin
Drug
Lead sponsor
Pacific Health Foundation
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
5
States / cities
San Diego, California • San Jose, California • Westminster, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Oct 17, 2026, 4:39 AM EDT
Terminated Phase 2 Interventional Results available

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

NCT01467505
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Immunosuppressant Regimen
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

NCT01726946
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
VX-135, ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
La Jolla, California • Orlando, Florida • Marietta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 17, 2026, 4:39 AM EDT
Completed Phase 4 Interventional

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

NCT02220868
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Sofosbuvir, Ribavirin, and Stribild
Drug
Lead sponsor
Saint Michael's Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 17, 2026, 4:39 AM EDT